Hormone pill treatment that may keep fertility for early womb lining cancer
Tests hormone pills in women with early, moderately grade womb lining cancer.
Plain-language title generated from the registry record
Registry title: Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women under 45 with stage IA grade 2 endometrioid endometrial cancer, limited to the lining of the womb, who strongly want to keep their fertility.
- Age
- Under 45 years
- Sex
- Women only
- Disease stage
- Endometrioid adenocarcinoma G2, confirmed by pathology. The lesion is limited to the endometrium. FIGO (2009) stage IA.
Main reasons for not taking part
- Tumor has grown into the muscle layer
- FIGO (2009) stage IB or higher
- Endometrioid adenocarcinoma G1 or G3, or non-endometrioid cancer
- Malignant tumors in other body systems
- Contraindications for conservative treatment or drug use
Read by machine on 12 November 2026.
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Yiqin WangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06468215
- Record updated
- 21 August 2026
- Original description
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.Read full original descriptionShow less
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Inclusion: Endometrioid adenocarcinoma G2, diagnosis by pathological; The lesion is limited to the endometrium; FIGO (2009) staging is IA; Age less than 45; Strongly request to preserve fertility; Sign informed consent.
Exclusion: Have contraindications for conservative treatment or drug use; Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer; There are malignant tumors in other systems; The tumor has invaded the muscle layer; FIGO (2009) stage IB or higher; Have been judged by the researcher to be unsuitable for childbearing.